Key result
Periprocedural SGLT2i is linked to ~56% lower 1-year atrial-arrhythmia recurrence in HF without T2DM.
Why the study?
The impact of SGLT2 inhibitors on catheter ablation outcomes for atrial fibrillation in heart failure patients without type-2 diabetes was unclear.
Does periprocedural SGLT2i treatment reduce atrial-arrhythmia recurrence in heart failure patients without type-2 diabetes undergoing catheter ablation for persistent AF?
Population
102 persistent AF and HF patients without type-2 diabetes undergoing catheter ablation
Comparison
SGLT2i prescribed from ≥1 month prior and continued vs no SGLT2i prescribed
Design
Prospective cohort study
Follow-up
1 year
Authors
Loading...
May support periprocedural SGLT2i to lower atrial arrhythmia recurrence in HF without T2DM; hypothesis-generating and requires randomized confirmation.
Cohort (n=102)
Does periprocedural SGLT2i treatment reduce atrial-arrhythmia recurrence in heart failure patients without type-2 diabetes undergoing catheter ablation for persistent AF?
Absolute Event Rate: 89% vs 75%
p-value: p=< 0.05
Periprocedural SGLT2i treatment in heart failure patients without diabetes undergoing catheter ablation for persistent AF is associated with decreased left atrial pressure and improved 1-year arrhythmia-free survival.
Harada et al. (2025) conducted a cohort in Persistent atrial fibrillation and heart failure without type-2 diabetes (n=102). Sodium-glucose cotransporter 2 inhibitors (SGLT2is) vs. No SGLT2i was evaluated on 1-year event-free rate of atrial-arrhythmia recurrence (p=< 0.05). Periprocedural SGLT2i treatment significantly increased the 1-year event-free rate of atrial-arrhythmia recurrence compared to no SGLT2i (89% vs. 75%, p < 0.05) in HF patients without T2DM.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: